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Abstract: Metabolic syndrome (MetS), a disorder with a high and growing prevalence, is a 
recognized risk factor for cardiovascular disease (CVD) and type 2 diabetes. It is a constellation 
of clinical and metabolic risk factors that include abdominal obesity, dyslipidemia, glucose intol-
erance, and hypertension. Unfortunately, MetS is typically underrecognized, and there is great 
heterogeneity in its management, which can hamper clinical decision-making and be a barrier to 
achieving the therapeutic goals of CVD and diabetes prevention. Although no single treatment 
for MetS as a whole currently exists, management should be targeted at treating the conditions 
contributing to it and possibly reversing the risk factors. All this justifies the need to develop 
recommendations that adapt existing knowledge to clinical practice in our healthcare system. In 
this regard, professionals from different scientific societies who are involved in the management 
of the different MetS components reviewed the available scientific evidence focused basically on 
therapeutic aspects of MetS and developed a consensus document to establish recommendations 
on therapeutic goals that facilitate their homogenization in clinical decision-making.
Keywords: cardiovascular prevention, diabetes prevention, insulin resistance, hypertension, 
dyslipidemia, obesity
Introduction
Metabolic syndrome (MetS) is defined as the aggregation of a set of risk factors in a 
single individual which can lead to the development of cardiovascular disease (CVD) 
and type 2 diabetes mellitus (T2DM), with insulin resistance (IR) being the pathogenic 
link. This may be conditioned by genetic but mainly exogenous factors, including 
abdominal obesity and physical inactivity. Because of this, the clinical phenotype of 
MetS appears years after IR, and its prevalence is proportional to age of the population 
and the presence of aggravating factors.
Among the metabolic alterations associated with MetS, the following stand out: 
1) dyslipidemia, mainly hypertriglyceridemia, a decrease in high-density lipoprotein 
(HDL) cholesterol, the presence of small and dense low-density lipoprotein (LDL) 
particles, together with a plasma increase in remnant triglyceride-rich lipoprotein 
particles and free fatty acids, and postprandial hyperlipidemia; 2) hyperglycemia or 
diabetes; and 3) arterial hypertension. These alterations, together with abdominal 
obesity, are the established parameters for the diagnosis of MetS.1 The diagnostic 
criteria established by different scientific societies and groups of experts are shown in 
Table 1.2–5 Other alterations such as non-alcoholic fatty liver, hyperuricemia or gout, 
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chronic inflammation, an increase in ultrasensitive C-reactive 
protein and cytokines, oxidative stress, hypercoagulable state 
with increased inhibitor of plasminogen activator type 1 
(PAI-1), and hyperfibrinogenemia have also been described.1–5
MetS is considered clinically significant owing to its high 
prevalence (0%–40% of the general population and 80%–
85% of patients with T2DM), its possible complications, and 
its potential reversibility and treatability. Complications are 
progressive and cumulative and associated with the degree 
of patient obesity and disease duration.6 
MetS identifies patients with a high risk of T2DM and 
CVD as well as numerous other complications. A recent 
meta-analysis indicated that those with MetS have a twofold 
increased risk of cardiovascular (CV) events and a 1.5-fold 
increased risk of death from all causes.7 Numerous studies 
analyzed the relationship between the MetS and T2DM. In 
a substudy of the Framingham Offspring Study, a relative 
risk of T2DM was increased by the number of the MetS 
components.8 A meta-analysis with 42,419 participants from 
16 cohorts found the relative risk of an incidence of T2DM 
to be 3.5–5.2 times higher, with no significant differences in 
the definition of the MetS used.9 More recent studies point to 
a relative risk of between 5 and 10 times for the development 
of T2DM.10 Finally, the association of obesity and cancer is 
increasingly significant: a higher incidence of breast, uterus, 
colon, esophageal, pancreatic, kidney, and prostate cancers 
has been found in obese patients.11 The possible complica-
tions associated with MetS, insulin resistance (IR), and 
abdominal obesity are shown in Figure 1.
Vascular risk in MetS
Several studies confirmed that patients with MetS have an 
increased risk of vascular complications such as coronary 
heart disease, stroke, and peripheral arterial disease.7,12 In 
general, an increase in risk barely differs according to the 
criteria used to define MetS, and CV risk is as high as the 
number of MetS components.7 For example, in a study car-
ried out by Klein et al,13 the risk of 5-year CVD varied from 
2.5% in patients with a single MetS component to 14.9% in 
those with four or more.
However, doubts remain as to whether the risk attributable 
to this syndrome is greater than the sum of its parts. The rela-
tive risk of death and CV complications attributable to MetS 
was reviewed in a meta-analysis that analyzed 87 studies 
with 951,083 participants and showed its association with a 
twofold increase in CV results (Table 2).7 Furthermore, the 
relative risk in females was significantly higher than that in 
males. When patients with T2DM were excluded from the 
analysis, the relative risk of CV events and deaths attribut-
able to MetS was reduced but remained significant (Table 3).
The increase in risk attributable to MetS has not only been 
observed in patients without diabetes in primary prevention 
but also in patients with coronary heart disease and those 
with T2DM.
Vascular risk in patients with established 
vascular disease and MetS
Data on the impact of MetS on the risk of new events develop-
ing in patients with established CVD are slightly discordant. 
Table 1 Criteria proposed by different international scientific societies for the diagnosis of the metabolic syndrome
Organization AHA/NHLBI/updated 
NCEP-ATPIII,3 2005
IDF4 (2005) JIS5 (2009)
Required criteria ≥3 of the following Central obesity (defined by waist 
circumference according to ethnicity) plus 
≥2 of the following
≥3 of the following
Fasting blood glucose ≥100 mg/dL ≥100 mg/dL ≥100 mg/dL
HDL cholesterol <40 mg/dL (♂)
<50 mg/dL (♀)
<40 mg/dL (♂)
<50 mg/dL (♀)
<40 mg/dL (♂)
<50 mg/dL (♀)
Triglycerides ≥150 mg/dL ≥150 mg/dL ≥150 mg/dL
Waist circumference ≥102 cm (♂)
≥88 cm (♀)
≥94 cm (♂)
≥80 cm (♀) 
(European population)
≥94 cm (♂)
≥80 cm (♀)
(Mediterranean population)
Hypertension ≥130/85 mmHg
or being treated 
≥130/85 mmHg
or being treated 
≥130/85 mmHg
or being treated 
Abbreviations: AHA/NHLBI/NCEP-ATPIII, American Heart Association/National Heart, Lung, and Blood Institute/National Cholesterol Education Program–Adult 
Treatment Panel III; IDF, International Diabetes Federation; JIS, Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; 
National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society, and International Association for 
the Study of Obesity; HDL, high-density lipoproteins.
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Although, in most studies, MetS increased the risk to the same 
level as that observed in patients without CVD,14,15 in other 
studies, the effect of MetS in patients with CVD appeared to 
be lower.16 In general, the relative risk of severe CV events 
associated with the presence of MetS in this population varied 
between 1.4 and 1.5 after patients with T2DM were excluded.
Vascular risk in patients with diabetes 
and MetS
Few studies analyzed the additional risk attributable to the 
MetS in patients with T2DM. In the FIELD study,16 conducted 
exclusively in patients with T2DM, MetS was accompanied 
by an increased risk of CV events. This effect was greater 
for participants who did not have CVD at the start of the 
study than for those who did. The higher the number of MetS 
Figure 1 Main comorbidities associated with the metabolic syndrome.
Abbreviations: GERD, gastro-esophageal reflux disease; PCOS, polycystic ovary syndrome; OSAS, obstructive sleep apnea syndrome.
 Metabolic 
syndrome
Nonalcoholic
fatty liver
Cardiovascuar
disease
GERD
Periodontal
disease
OSAS
Some types of
cancer
Osteoarthritis
Chronic kidney
disease
Microalbuminuria
Gestational
diabetes
Diabetes
PCOS
Depression
Cognitive
 impairment
Table 2 Relative risk of cardiovascular events and death in 
patients with metabolic syndrome*
Outcomes Relative risk (95% CI)
Total Male Female
Total mortality 1.58 (1.39–1.78) 1.42 (1.16–1.74) 1.86 (1.37–2.52)
CV mortality 2.40 (1.87–3.08) 1.94 (1.20–3.14) 2.55 (1.41–4.60)
CV disease 2.35 (2.02–2.73) 2.14 (1.62–2.83) 2.87 (2.40–3.43)
Myocardial 
infarction
1.99 (1.61–2.46) 2.01 (1.52–2.67) 2.57 (0.87–7.57)
Stroke 2.27 (1.80–2.85) 2.00 (1.38–2.88) 2.59 (1.94–3.46)
Note: *When compared with patients without metabolic syndrome.
Abbreviation: CV, cardiovascular.
Table 3 Relative risk of cardiovascular events and death in non-
diabetic patients with metabolic syndrome*
Outcomes Relative risk (95% CI)
Total mortality 1.32 (0.65–2.67)
CV mortality 1.75 (1.19–2.58)
Myocardial infarction 1.62 (1.31–2.01)
Stroke 1.86 (1.10–3.17)
Note: *When compared with patients without metabolic syndrome.
Abbreviation: CV, cardiovascular.
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criteria, the higher the risk. In the Strong Heart Study with 
patients who did not have CVD,17 the risk of fatal or nonfatal 
CV complications was higher in patients with MetS whether 
or not they had diabetes at the start of follow-up. Having MetS 
implies an increased risk of CV complications and death. This 
is valid in patients in primary prevention with and without 
T2DM and in those with established CVD.
However, the diagnosis of MetS implicitly carries, in a 
significant number of cases, a diagnosis of hypertension, a 
risk factor already included in the risk estimation charts. 
Therefore, including MetS in the estimation of risk by directly 
multiplying the risk emerging from a risk equation by the 
relative risk attributable to the MetS would imply magnify-
ing this risk, as hypertension has been considered twice. 
This is, at least in part, the reason why no consensus exists 
as to how the MetS should modulate the risk emerging from 
CV risk equations. In this regard, the latest 2016 European 
guidelines on CV prevention do not refer to the MetS but 
state that obesity, particularly central obesity, could play a 
modulating role in risk.18 Meanwhile, when addressing the 
debate regarding the increase in CV risk in the population 
with the MetS, the European Society of Cardiology (ESC) 
and European Atherosclerosis Society (EAS) guideline for 
the control of dyslipidemia suggests that the combination of 
increased waist circumference and elevated triglycerides is a 
simple and inexpensive screening tool to filter patients with 
MetS who have a high CV risk.19
Abdominal obesity
Obesity and MetS are two closely related complex entities 
whose growing prevalence in the population has become a 
serious public health problem in Western countries. From 
a clinical perspective, the difficulty lies in identifying the 
effect attributable to each entity when estimating the risk 
of developing CVD or T2DM. However, control of these 
metabolic alterations also directly affects the morbidity and 
mortality of other chronic diseases (Figure 1), which obli-
gates to establishing effective preventive, diagnostic, and 
therapeutic strategies. Although both processes do present 
together, it is well established that they are not necessarily 
associated. The presence of abdominal obesity has a negative 
impact on the different components of MetS such as blood 
pressure, waist circumference, plasma glucose levels, HDL 
cholesterol, and triglycerides.20 It is important to emphasize 
that the most accepted and constant diagnostic parameter for 
MetS is central obesity, calculated using body mass index 
(BMI) and waist circumference, with the latter being a vari-
able depending on the ethnicity and sex of the patient being 
analyzed. In our milieu, we consider abdominal obesity to 
be waist circumference, measured just above the iliac crests, 
≥94 cm in Caucasian males or ≥80 cm in Caucasian females.1 
Its importance is based on the fact that central obesity is one 
of the most significant triggers of other metabolic alterations 
in the pathogenesis of the MetS, including IR. This explains 
the presence of MetS in obese patients, in most cases, and that 
it is largely a comorbidity of obesity. Finally, it is important 
to point out that the use of uniform definitions of obesity 
and MetS is crucial for the detection of both conditions in 
routine clinical practice.21 
When considering the diagnosis of these processes, their 
progressive nature should be noted and that they include dif-
ferent clinical stages. Initially, they debut with the presence 
of causative factors (central adiposity and IR, together with 
the genetic component that characterizes each patient) and 
subsequently lead to the aforementioned metabolic alterations 
(hypertension, dyslipidemia, and alteration of hydrocarbon 
metabolism). Next, vasculopathy develops in an initial sub-
clinical stage, and atherothrombotic complications and the 
development of T2DM finally appear. For this reason, we 
should not only limit diagnosis to the presence of metabolic 
alterations but also consider the possibility of preestablished 
subclinical alterations.
Since suitable lifestyle changes significantly reduce the 
risk factors associated with MetS, management of both the 
processes should include recommendations for a healthy 
lifestyle, emphasizing physical activity, a healthy eating plan, 
and smoking and alcohol avoidance. In this respect, a group 
of international experts recently defined a set of lifestyle 
recommendations for the prevention and treatment of MetS, 
including aspects regarding weight control.22
Hyperglycemia/diabetes
Since most of the patients with MetS have IR, an overlap 
between the prevalence of hyperglycemia and the MetS is 
not surprising. The latter has traditionally been considered a 
prediabetic state; compared to patients without MetS, those 
with MetS have fourfold greater risk of T2DM.23
In the evolution of MetS and as a consequence of IR, 
compensating hyperinsulinism appears which can temporar-
ily maintain glucose metabolism within the normal range. 
Subsequently, alteration in glucose metabolism (prediabetes 
or diabetes) appears because of a deficit, at least relative, of 
insulin secretion. Several methods have been developed to 
assess peripheral insulin sensitivity. Of the in vivo methods, the 
hyperinsulinemic euglycemic clamp stands out and is consid-
ered the gold standard. In clinical practice, indirect formulae 
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such as the homeostatic model assessment-insulin resistance 
(HOMA-IR) index are used. In our experience, based on a 
Valencian and Spanish population, we defined IR as baseline 
or fasting plasma insulin ≥14 mU/L or HOMA
IR
 [insulin mU/L 
× glucose mmol/L/22.5]) ≥3.2. Clinically, abdominal obesity 
and hypertriglyceridemia indicate a high probability of IR that 
rises if blood glucose levels are altered.24 
Increased risk categories for diabetes
These are fundamentally impaired glucose tolerance (IGT) 
and impaired fasting blood glucose (IFG). The first is 
considered when plasma glucose ranges from 140 mg/dL to 
199 mg/dL at 2 hours of an oral glucose tolerance test (OGTT) 
(75 g) and IFG from 100 mg/dL to 125 mg/dL in fasting. Also, 
diabetes is understood to exist when fasting blood glucose 
values are ≥126 mg/dL or ≥200 mg/dL at 2 hours of OGTT.25
Recently, plasma glycosylated hemoglobin (HbA
1c
) 
levels have been begun to be used for the diagnosis of 
prediabetes and diabetes. Levels between 5.7% and 6.4% are 
considered diagnostic of prediabetes, whereas levels ≥6.5% 
are considered diagnostic of diabetes.25
The development of T2DM is associated with an 
increased CV risk of 2–4 times higher than the rate observed 
in the population of similar age and sex without diabetes,26,27 
which is considered a situation of high CV risk. Recently, 
the American Association of Clinical Endocrinologists and 
the American College of Endocrinology (AACE-ACE) 
considered T2DM to be a high CV risk.28 T2DM associated 
with a risk factor (either high LDL cholesterol, smoking, 
hypertension, HDL cholesterol <40 mg/dL, family history of 
CVD in first-degree male relatives aged <55 years or female 
relatives aged <65 years, stage 3/4 chronic kidney disease, 
coronary calcification, and males aged ≥45 years or females 
aged ≥55 years) is considered a very high CV risk. Finally, 
the category of extreme CV risk is established in patients 
with T2DM and clinically established CVD, in which a target 
LDL cholesterol <55 mg/dL is recommended.
Treatment of hyperglycemia and diabetes 
An improvement in glycemic control yielded no significant 
impact on CVD prevention, possibly due to the study 
designs or because desirable HbA
1c
 levels were not reached 
and maintained long enough and with drugs without the 
hypoglycemic risk, although a reduction in the number of 
CV events was observed.27
Lifestyle modification is essential for correct control of 
hyperglycemia and IR, and consequently all components of 
MetS. In the short–medium term, adherence to a low  glycemic 
load/high fiber-content diet is sufficient for the control of 
hyperglycemia.29 A Mediterranean diet relatively rich in 
vegetable fats has also been confirmed as effective. There is 
evidence that a loss of 7% of initial body weight following a 
healthy diet and carrying out moderate physical activity (such 
as brisk walking) of at least 150 minutes/week can prevent the 
development of diabetes in predisposed individuals.30
The pharmacological treatment of T2DM includes the use 
of oral antidiabetics in monotherapy or in combination with 
noninsulin injectable drugs and insulin. Insulin-sensitizing 
antidiabetics such as metformin and glitazones (pioglitazone) 
reduce IR, improve metabolic control, hypertension, 
dyslipidemia, and other components of MetS, and are 
essential in the treatment of T2DM with MetS.
Similarly, antidiabetics that lower the patients’ weight 
such as glucagon-like peptide-1 (GLP-1) receptor agonists 
and SGLT-2 inhibitors play an important role. Some anti-
diabetics have recently been shown to reduce CV events in 
patients with T2DM and established CVD (empagliflozin, 
liraglutide, and canagliflozin).31–33
In the treatment of MetS, some antidiabetics may play a 
protective role in preventing progression to T2DM. In patients 
with prediabetes (MetS), metformin has been shown to assist 
in the prevention of diabetes by 25%–30%30 and pioglitazone 
by 72%.34 Conversely, pioglitazone has also been shown to 
be effective in diabetes prevention in patients with fatty liver 
and for the control of fatty acid supply to the liver.35
GLP-1 receptor agonists reduce prediabetes or conversion 
to T2DM. Currently, although not funded by the public health 
system, a high-dose liraglutide (3 mg) formula has become 
available, which the SCALE program has found to be effec-
tive for weight loss and in reducing the risk of progression 
from prediabetes to diabetes.36,37
Since no data are available on the goal of glycemic control 
in patients with MetS without T2DM, the routine use of an 
antidiabetic drug is not recommended. However, preventive 
treatment with metformin can be considered in patients with 
IGT, IFG, or HbA
1c
 level of 5.7%–6.4%, particularly if they 
have a BMI >35 kg/m2, are under 60 years, and are females 
with previous gestational diabetes.38
An alternative to pharmacological treatment is bariatric 
surgery, when BMI >40 kg/m2 or >35 kg/m2 plus comorbidi-
ties are associated with excess weight.
Arterial hypertension
No changes to the blood pressure criteria for MetS have 
been suggested by either the National Cholesterol Educa-
tion Program–Adult Treatment Panel III (NCEP-ATPIII)2 
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or the International Diabetes Federation4 and following 
the consolidations of the American Heart Association/
National Heart, Lung, and Blood Institute Document (AHA/
NHLBI).3 Most clinical guidelines for the diagnosis and 
treatment of hypertension do not currently consider MetS 
as a modifier of therapeutic recommendations.39–41 In gen-
eral, the criteria for starting pharmacological treatment are 
established at 140/90 mmHg. Specific interventions for indi-
viduals with lower levels have not been described beyond 
general population recommendations to reduce salt intake, 
maintain an adequate weight, and practice physical exercise.
In hypertensive individuals, reducing to levels below 
140/90 mmHg is recommended.39–41 Values <150 mmHg 
are considered acceptable in patients aged >80 years or in 
those aged > 60 years and are very fragile and/or at risk of 
falls due to orthostatic hypotension.39–41 The ESC CV pre-
vention guideline also recommends SBP <140 mmHg for all 
 hypertensive patients aged <60 years.19 In patients aged >60 
years with SBP >160 mmHg, lowering their SBP to 140–150 
mmHg is recommended.19
In hypertensive individuals with diabetes, a reduction in 
SBP to <140 mmHg is suggested.39–41 Recommendations for 
DBP levels are not the same in all guidelines but are mostly 
<90 mmHg.40,41 The 2013 European guideline suggests reduc-
ing it to <85 mmHg.39
Recently, the SPRINT study showed the benefits of a 
reduction in SBP to <120 mmHg.42 However, since the meth-
ods used for measuring blood pressure were not like those 
normally used in clinical practice, the results could not be 
easily generalized and, in any event, would have corresponded 
to values close to 130 mmHg if conventionally measured. The 
patients in that study were hypertensive without diabetes but 
had a high CV risk. The proportion of patients with MetS 
was unknown, and a subgroup analysis was not specified in 
those patients.
In November 2017, the American College of Cardiology, 
AHA, and related societies’ guideline modif ied the 
diagnostic criteria for hypertension, establishing them 
at levels >130 and/or 80 mmHg and recommended 
modifications in all patients’ lifestyles based on these 
figures, in addition to antihypertensive pharmacological 
treatment for levels ≥140 and/or 90 mmHg or levels ≥130 
and/or 80 mmHg if 10-year CV risk is >10% according 
to the risk chart equation.43 This risk estimate considers 
MetS components such as diabetes and HDL cholesterol. 
On this basis, many patients with MetS and blood pressure 
levels ≥130 and/or 80 mmHg would be candidates for 
pharmacological therapy.
Treatment
No comparative studies have been conducted among anti-
hypertensive drugs that have included CV morbidity and 
mortality objectives in patients with MetS. Indirect evi-
dence suggests that drugs that inhibit the renin angiotensin 
system (angiotensin converting enzyme inhibitors [ACEI] 
and angiotensin II receptor blockers [ARB-2]) and calcium 
channel blockers have neutral effects on IR and are equally 
neutral or slightly positive on the onset of diabetes.44 Other 
first-line pharmacological groups such as thiazide diuretics 
and beta-blockers increase IR and the risk of developing de 
novo T2DM.
Dyslipidemia of MetS
Pathogenic bases
MetS favors the development of atherosclerosis, and its 
characteristic dyslipidemia contributes to it significantly. It 
comprises two lipid alterations that contribute to its diagnos-
tic criteria: fasting triglyceridemia >150 mg/dL and an HDL 
cholesterol concentration <40 mg/dL in males and <50 mg/
dL in females. Its base is increased synthesis of very low-
density lipoproteins (VLDL), since liver is overexposed to an 
excess of free fatty acids from adipose tissue, a reduction in 
the lipolytic capacity of plasma and an increase in the activity 
of cholesterol ester transfer protein, which involves reducing 
the cholesterol content of HDL.17,45
Low HDL cholesterol is a recognized independent risk 
factor.46 The protective action of HDL has been associated 
with its ability to remove cholesterol from peripheral tissues 
and its antioxidant effect that prevents the oxidation of LDL in 
the subendothelial space. Although this association is close, 
Mendelian randomization and pharmacological intervention 
studies have not shown a clinical benefit in the increase in 
HDL cholesterol.47 The REVEAL study recently showed that 
adding anacetrapib (100 mg/day) to intensive statin therapy 
for ~4 years results in a lower incidence of severe coronary 
events compared to adding placebo in patients with CVD and 
baseline levels of controlled LDL cholesterol (mean, 61 mg/
dL [1.58 mmol/L]).48 A 9% reduction in CV events cannot be 
explained by the doubling of HDL cholesterol levels alone, 
and the reduction in non-HDL cholesterol seemed to be the 
main cause of the observed effect of anacetrapib.
By contrast, although the association between hyper-
triglyceridemia and CV risk is weakened when adjusted 
for other factors, recent Mendelian randomization studies 
indicate that triglyceride-rich lipoproteins play a key role in 
the predisposition to atherosclerosis. Triglycerides do not 
accumulate like cholesterol in atheromatous plaque and are 
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thus indirectly atherogenic, either through the lowering of 
HDL cholesterol or by the accumulation of lipoproteins with 
direct atherogenic capacity. First, there is an increase in LDL 
particles enriched in triglycerides and depleted in cholesterol 
which, in addition to changing their density, makes them 
smaller, giving them greater ability to infiltrate the arterial 
wall, become trapped by proteoglycans in the subendothelial 
space, and oxidize. Second, hypertriglyceridemia leads to the 
accumulation of VLDL and chylomicron remnant particles 
which, because of their size, cross into the subendothelial 
space and contribute, like LDL, to atheromatous plaque. 
Third, an overproduction of VLDL increases competition 
with chylomicrons for lipoprotein lipase such that the latter 
can accumulate during fasting.49
Since all apoB-containing particles are atherogenic, quan-
tifying this apoprotein as an expression of VLDL, IDL, and 
LDL has been suggested. In its absence, the quantification 
of non-HDL cholesterol concentration provides the clinician 
with a useful tool for measuring all atherogenic cholesterol.50
In recent years, lipoprotein(a) [Lp(a)] as a CV risk factor 
has been revisited, mainly in patients with familial hypercho-
lesterolaemia.51 For unknown reasons, hypertriglyceridemia 
and other components of the MetS, particularly those related 
to IR, showed an inverse association with Lp(a) concentra-
tions.52 Furthermore, Lp(a) levels in patients with coronary 
heart disease were predictors of CVD only in patients without 
MetS.53
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is 
a protein that regulates the expression of LDL receptors and, 
consequently, circulates LDL cholesterol levels.54 PCSK9 
concentrations in the MetS and atherogenic dyslipidemia are 
high compared with patients without MetS.55,56 In addition, 
change from a typical American diet to a Mediterranean diet 
in patients with MetS results in a drop in PCSK9 concentra-
tion and a consequent reduction in LDL cholesterol.57
All these data taken together suggest that dyslipidemia 
associated with MetS contributes to increased CV risk.
Dyslipidemia
Atherogenic dyslipidemia, typical of the MetS, includes 
an increase in triglycerides and remnant particles in both 
 postprandial and fasting states, a deficit of HDL cholesterol 
and apoA1 and an excess of apoB associated with predomi-
nance of small and dense LDL particles. This dyslipidemia is 
also characteristic of T2DM and abdominal obesity. Among 
all the lipid alterations of atherogenic dyslipidemia, the 
excess of apoB-containing lipoproteins is the most remark-
able owing to its atherogenic potential. The sum of the 
cholesterol contained in these lipoproteins corresponds to 
non-HDL cholesterol and is calculated simply by subtract-
ing HDL cholesterol from total cholesterol. The reference 
levels of non-HDL cholesterol are those obtained by adding 
0.8 mmol/L (30 mg/dL) to the reference values of LDL 
cholesterol. We have seen in patients with MetS that non-
HDL cholesterol is a better predictor of CV risk than LDL 
cholesterol. This is due to the fact that Friedewald’s formula 
loses precision in the calculation of LDL cholesterol when 
there is hypertriglyceridemia, given that non-HDL cholesterol 
includes all apoB lipoproteins which are atherogenic. Non-
HDL cholesterol has a strong correlation with serum apoB 
concentration.58 In some studies, apoB, which is equivalent 
to the total number of atherogenic lipoprotein particles, cor-
related more strongly with CV risk and was a better predictor 
of the protective effect of statins against CVD and of achiev-
ing therapeutic targets than LDL cholesterol or non-HDL 
cholesterol, but not in all of them.59,60 Laboratory methods 
for measuring apoB are standardized, but are not available 
in all clinical laboratories and imply an additional cost; thus, 
non-HDL cholesterol is most often used in clinical practice. 
Discrepancies among apoB, LDL cholesterol, and non-HDL 
cholesterol are greater in patients with MetS.61 Similarly, a 
reduction in LDL and non-HDL cholesterol obtained with 
statins is proportionally greater than a decrease in apoB. 
Therefore, it is more difficult to reach apoB targets than those 
of LDL cholesterol or non-HDL cholesterol.62
On the other hand, large clinical intervention studies have 
shown that lower the atherogenic cholesterol is, the greater the 
preventive effect will be against CVD,63 which is consistent 
with the fact that the harmful effect of atherogenic cholesterol 
on the arterial wall is greater in patients with MetS or IR than 
in individuals without such disorders.64
In patients with atherogenic dyslipidemia, the main 
therapeutic goal is to reduce non-HDL cholesterol, although 
if there is no excess of triglycerides (<200 mg/dL), LDL 
cholesterol can also be considered. The first-choice drugs to 
achieve this goal are statins. They lower CV risk by 23% per 
mmol/L (~40 mg/dL) of LDL cholesterol decrease, regardless 
of baseline concentrations or other patient characteristics.65 
Thus, the reduction in relative risk obtained by treating with 
statins is similar in patients with and without MetS or T2DM. 
However, if we also consider that the absolute CV risk of 
patients with T2DM or MetS is higher, then the absolute 
benefit of the treatment – that is, the number of cases of 
CVD avoided – is also greater, and thus fewer patients will 
be treated and the economic cost that has to be allocated to 
avoiding CV events will be lower. 
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
690
Pedro-Botet et al
Strong evidence from meta-analyses and other clinical 
studies using high doses of statins shows that a reduction in 
LDL cholesterol – even in individuals with normal or low 
LDL cholesterol – reduces mortality, in both primary and 
secondary prevention settings, and that patients with MetS 
benefit more from the use of statins than those without, 
perhaps because their CV risk is higher.66,67
Non-HDL and LDL cholesterol and apoB targets for 
patients with high or very high CV risk according to the 2016 
ESC/EAS guideline19 and the National Lipid Association68 
are shown in Table 4. A wide evidence is provided by clinical 
trials in patients with MetS to justify these objectives.16,69,70 
As mentioned, statins lower non-HDL cholesterol to a greater 
extent than apoB, and a more aggressive treatment is needed 
to achieve apoB targets than to reach non-HDL cholesterol 
targets.71–73
Dietary measures and lifestyle improvements are essential 
for all patients with MetS to prevent both CVD and T2DM.74
The first-choice pharmacological treatment to achieve 
non-HDL cholesterol targets in patients with MetS is 
moderate to high intensity statins. Among the former, 
which lowers LDL cholesterol by between 30% and 50%, 
are atorvastatin at a dose of 10–40 mg/day, rosuvastatin 
5–10 mg/day,  simvastatin 20–40 mg/day, pitavastatin 2–4 
mg/day, pravastatin 40 mg/day, and fluvastatin 80 mg/day. 
High-intensity statins, which lower LDL cholesterol by at 
least 50%, include atorvastatin at a dose of 80 mg/day or 
rosuvastatin at 20–40 mg/day.75 If the LDL or non-HDL 
cholesterol target is not achieved with a statin in monotherapy 
at the maximum tolerated dose, ezetimibe can be combined, 
providing an additional 20%–25% reduction. In this respect, 
the hypocholesterolemic efficacy of a statin-ezetimibe asso-
ciation has been observed to be the same in patients with and 
without MetS.76
Another aspect to consider when selecting a statin is the 
risk of intolerance or side effects that is somewhat greater 
in MetS patients.77 Since these patients are usually being 
treated with multiple drugs, statins that have lower potential 
for drug interactions such as rosuvastatin and pitavastatin 
should be used. Another aspect to consider is the potential 
of statins to alter glucose metabolism, an effect which, 
although small, is more significant in patients with MetS, 
since this population has a higher risk of developing T2DM. 
Unlike other statins, pitavastatin has been shown to lack a 
diabetogenic effect,78 a characteristic that Spanish primary 
and specialized healthcare professionals are already well 
aware of and which was discussed in a recent consensus 
document on the treatment of dyslipidemia in patients with 
impaired glucose metabolism.79,80
An anti-PCSK9 monoclonal antibody, that is, alirocumab 
or evolocumab, can be used for patients with MetS who do not 
reach non-HDL cholesterol targets with prior lipid-lowering 
drugs. However, the use of these new drugs is restricted for 
the time being to patients in secondary prevention and those 
with familial hypercholesterolemia whose LDL cholesterol 
falls outside targets despite treatment with statins at maxi-
mum tolerated doses.81
Fibrates have been used with good results in primary 
and secondary prevention in situations characterized by 
increased triglycerides with or without low HDL cholesterol, 
which is very common in patients with T2DM and MetS. 
Consequently, clinical guidelines such as the International 
Atherosclerosis Society 2014,60 EAS/ESC 2016,19 Sociedad 
Española de Arteriosclerosis (SEA) 2017,82 and AACE-ACE 
201728 recommend the use of fibrates in patients at high/very 
high CV risk when there is an increase in triglycerides, non-
HDL cholesterol, or atherogenic dyslipidemia, once LDL 
cholesterol has been controlled. A recent Cochrane review in 
primary prevention showed that the benefit emerges from the 
reduction in a combined objective of CV mortality, nonfatal 
infarction, and nonfatal stroke (–16%), or a combination 
of coronary mortality and nonfatal infarction (–21%), with 
no significant changes in non-CV mortality or any cause.83 
In another Cochrane review on secondary prevention,84 the 
benefit arises from the reduction in a combined objective of 
CV mortality, infarction (fatal and nonfatal), and stroke (fatal 
and nonfatal) (–12%) as well as a significant reduction in 
myocardial infarction (fatal and nonfatal) (–14%). The maxi-
mum benefit of fibrate therapy is found when atherogenic 
dyslipidemia is present; in this specific group, the relative 
CVD risk is reduced by up to 35%.
MetS: a prothrombotic state
Patients with MetS have hemostatic alterations that can raise 
both atherothrombotic and thromboembolic CV risk.85 Both 
are caused by a reduction in vasodilator agent activity and an 
Table 4 Primary objectives of treatment of atherogenic 
dyslipidemia in patients with metabolic syndrome
Cardiovascular 
risk
LDL  
cholesterol
Non-HDL  
cholesterol
ApoB
High CVR <100 mg/dL
(2.6 mmol/L)
<130 mg/dL
(3.4 mmol/L)
<100 mg/dL
Very high CVR <70 mg/dL
(1.8 mmol/L)
<100 mg/dL
(2.6 mmol/L)
<80 mg/dL
Abbreviations: CVR, cardiovascular risk; LDL, low-density lipoproteins; HDL, 
high-density lipoproteins; Apo, apolipoprotein.
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increase in the expression of vasoconstrictors as a consequence 
of endothelial dysfunction. This dysfunction is the result of 
chronic inflammation, dyslipidemia, and hypertension. There is 
also a hypercoagulability state related to impaired liver produc-
tion of coagulation factors and proinflammatory cytokines as a 
consequence of IR.86 This hypercoagulability is accompanied 
by impaired fibrinolysis and platelet dysfunction,87,88 a result 
of high levels of PAI-1,87,89 tissue factor,90,91 fibrinogen,89 and 
factor VIII activity.92 Jointly, evidence exists of the effect of 
several adipokines, such as leptin and adiponectin, on platelet 
function,93 with increased baseline platelet reactivity, lower 
antiplatelet response to aspirin,92 and increased risk of venous 
thrombosis being described in MetS.94
From a therapeutic perspective, caloric restriction and 
weight loss are accompanied by a reduction in the activation of 
coagulation factors.95 Specific pharmacological therapies other 
than aspirin to treat the prothrombotic state of patients with 
MetS are still not available. It should be noted that many of the 
factors involved in the hypercoagulability state of MetS are not 
significantly affected by acetylsalicylic acid and, therefore, its 
benefit cannot be assumed. In addition, no specific intervention 
studies have been conducted in this population, and thus data 
on the usefulness of aspirin therapy in patients with MetS are 
limited. Antiplatelet therapy with aspirin is a well-established 
treatment for the prevention of coronary events in patients 
with acute or chronic ischemic heart disease with or without 
T2DM.96 Therefore, aspirin should be recommended in patients 
with MetS in secondary prevention. By contrast, the CV ben-
efits of antiplatelet therapy in primary prevention are scant 
and partially offset by the risk of bleeding, even when used in 
patients with risk factors such as diabetes or hypertension.97
Recommendations
The main clinical control recommendations for each com-
ponent of MetS are shown in Table 5.
Abdominal obesity
Abdominal obesity defined by a high waist circumference 
according to sex and ethnicity (≥94 cm in Caucasian males 
and ≥80 cm in Caucasian females) and MetS are two closely 
related complex entities whose coexistence has become a 
serious health problem owing to an increase in the risk of 
CVD or T2DM. This situation has forced us to propose effec-
tive prevention and treatment strategies.
Treatment
Physical exercise and a healthy diet are the therapeutic pil-
lars against obesity. MetS patients’ control of their caloric 
intake is a fundamental part of their treatment, since weight 
loss of 5%–10%, particularly if there is a preexisting 
overweight or obesity, notably improves glycemic control, 
lipid profile, and blood pressure. In addition, the nutritional 
quality of their diet must be improved, replacing foods with 
a greater diabetogenic and atherogenic effect by those who 
are more CV healthy. Reducing the saturated fat intake of 
daily calories by <10%, eliminating foods containing trans 
fatty acids, lower salt consumption, not consuming products 
with added sugar or other refined foods, consuming food 
with low glycemic carbohydrates – which will enhance 
fiber consumption by up to at least 15 g/1,000 kcal – and 
prioritizing specific food that are rich in nutrients such as 
legumes, whole grains, nuts, vegetables, and fruit are recom-
mended as following these instructions has been found to 
correlate with a reduced CV risk.98 The Mediterranean diet 
model serves to guide patients with MetS and help control 
their CV risk.99 DASH or vegetarian diets, emphasizing the 
consumption of fruits, vegetables, legumes, and fish and 
limiting or reducing meats and saturated fats, are dietary 
patterns low in saturated fatty acids, cholesterol, and sodium 
and high in fiber, potassium, and unsaturated fatty acids, 
which have been shown to be beneficial for these patients 
by reducing CV risk.100,101
IR is a common feature of obesity and MetS. For this 
reason, increasing insulin sensitivity has been shown to be 
effective in improving the control of certain MetS components 
(blood pressure, HDL cholesterol, triglycerides, and glyce-
mia). Weight loss or certain medications, such as metformin, 
may increase insulin sensitivity. Furthermore, currently  certain 
drugs are approved by the European Medicines Agency, such 
as orlistat, the combination of naltrexone + bupropion, and 
liraglutide, which facilitate effective weight loss.102,103
Bariatric surgery is also an effective therapeutic option 
in morbidly obese patients or in those with a lower degree 
of obesity but who have associated CV risk factors.104 In 
addition, each anomaly associated with obesity and/or MetS 
should be addressed per individual, such as encouraging the 
patient to carry out regular physical exercise and give up 
smoking and alcohol consumption.
In summary, evidence showing that a high proportion of 
adults in developed societies present obesity and MetS, with 
a consequent increase in the risk of developing T2DM and 
CVD in the short/medium term exists. Lifestyle, especially 
physical exercise and diet, is the fundamental pillar of treat-
ment which must include a weight loss of 5%, mainly in 
overweight or obese patients, in order to improve glycemic 
control, lipid profile, and blood pressure levels.
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Hyperglycemia/diabetes
An OGTT (75 g) and HbA
1c
 should be requested for patients 
with MetS who do not meet diabetes criteria (see increased 
risk categories for diabetes). Considering the presence or 
absence of hyperglycemia to establish the patients’ CV risk 
is recommended.
Treatment 
A CV healthy lifestyle is essential for correct hyperglyce-
mia and IR control and, consequently, all components of 
the MetS. A diet with a low content of rapidly digestible, 
simple carbohydrates, and high fiber content is sufficient to 
control hyperglycemia.29 Following a Mediterranean, diet 
has also been shown to reduce the occurrence of diabetes in 
at-risk individuals.105 A 7% loss of initial body weight and an 
increase in moderate physical activity (such as brisk walking) 
of at least 150 minutes/week can prevent the development 
of diabetes in predisposed individuals.30 Furthermore, data 
also demonstrate that resistance/strength exercises together 
with aerobic exercise are even more effective in preventing 
diabetes.106
The routine use of an antidiabetic drug is not recommended 
in patients with MetS/prediabetes. However, preventive 
treatment with metformin can be considered in cases with 
IFT, IGT, or an HbA
1c
 level of 5.7%–6.4%, particularly if they 
have a BMI >35 kg/m2, are aged <60 years, and are females 
with prior gestational diabetes.38
In patients with MetS and liver steatosis, the use of pio-
glitazone could be relevant and, in those with a diagnosis 
of diabetes mellitus, insulin-sensitizing antidiabetics such 
Table 5 Therapeutic goals and clinical control of the metabolic syndrome
Component Therapeutic objective Observations
Abdominal 
obesity
Achieve a 5%–10% weight loss and carry out an aerobic 
physical activity program that includes at least 30–60 
minutes a day of exercise adapted to the physical 
condition of the individual
Promote physical exercise and adopting a healthy diet such as the 
Mediterranean, DASH, or vegetarian diets
Avoid a sedentary lifestyle
Fasting blood 
glucose
Basal glycemia <100 mg/dL in patients without diabetes.
If there is already a diagnosis of diabetes, the fasting 
blood glucose target should be personalized given 
that, similar to HbA1c, the objective will depend on the 
existence of comorbidities and the risk of hypoglycemia, 
among others
In patients with prediabetes, a change of lifestyle is necessary – 
personalized diet and physical activity plan. The use of metformin 
can be considered in patients with impaired basal glycemia or 
glucose intolerance, who also have a BMI >35 kg/m2, aged <60 
years, or are female with prior gestational diabetes
In patients with T2DM, metformin is the drug of choice.
When adding more drugs is necessary (HbA1c falls outside the 
personalized target), those with a low risk of hypoglycemia are 
recommended (DPP4i, SGLT2i, GLP-1 receptor agonists), with 
the first choice being SGLT2i and/or GLP-1 receptor agonists in 
cases of obesity
When CVD is already present, using SGLT2i (empagliflozin, 
canagliflozin) or GLP-1 receptor agonists (liraglutide) is 
recommended
BP Reduce BP to <140/90 mmHg in all patients. In high-risk 
patients, a target <130/80 mmHg may be recommended 
if it is well tolerated
Drugs that block RAS and calcium antagonists have a neutral or 
favorable profile on lipid and hydrocarbon metabolism and are 
recommended as first choice provided there are no other specific 
indications or contraindications
Lipids LDL cholesterol ≤100 mg/dL (≤70 mg/dL in very high-risk 
patients)
Non-HDL cholesterol ≤130 mg/dL (≤100 mg/dL in very  
high-risk patients)
Triglycerides ≤150 mg/dL
HDL cholesterol ≥40/50 mg/dL (male/female)
The desirable level of LDL cholesterol or non-HDL cholesterol 
depends on the patients’ CV risk. To achieve targets in very high-
risk patients, a high-potency statin and dose should be selected 
(atorvastatin 40–80 mg, pitavastatin 2–4 mg, or rosuvastatin 
20–40 mg). In the presence of prediabetes, polypharmacy or 
pluripathology, including renal failure, consider the use of a statin 
such as pitavastatin that does not alter hydrocarbon metabolism 
or that has a favorable interaction and safety profile, respectively
If an excess of LDL cholesterol or non-HDL cholesterol persists, 
consider associating with ezetimibe
If hypertriglyceridemia persists, once the LDL cholesterol is 
controlled, but non-HDL cholesterol is out of goals, consider the 
addition of a fibrate (fenofibrate)
Abbreviations: CV, cardiovascular; CVD, cardiovascular disease; BP, blood pressure; RAS, renin angiotensin system; BMI, body mass index; LDL, low-density lipoprotein; 
HDL, high-density lipoprotein; DASH, dietary approaches to stop hypertension.
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as metformin and glitazones (pioglitazone) are basic in the 
treatment of T2DM with MetS.
Similarly, GLP-1 receptor agonists and SGLT-2 inhibitors, 
accompanied by significant weight loss, should be seriously 
considered. Patients with T2DM and CVD should be treated 
with antidiabetics with clearly demonstrated CV benefits such 
as empagliflozin, liraglutide, and canagliflozin.31–33
Bariatric surgery can be considered in cases with a 
BMI >40 or >35 kg/m2 plus comorbidities related to excess 
weight.104
Arterial hypertension
The general recommendation for all hypertensive patients 
with MetS is to make healthy changes in their lifestyle such 
as losing weight by limiting caloric intake and increasing 
physical exercise as well as reducing salt consumption.39–41 
In addition, hypertensive patients with MetS should receive 
pharmacological treatment aimed at reducing blood pres-
sure to levels <140/90 mmHg. Recommendations for a 
more intense reduction (<130 mmHg of SBP), based on the 
results emerging from the SPRINT study,42 could be applied 
to hypertensive patients with MetS – who have a high CV 
risk, according to the Framingham algorithm or CVD – but 
who do not have T2DM or a history of stroke.
Treatment
Except for specific indications of other therapeutic options or 
contraindications, when choosing pharmacological treatment, 
drugs that inhibit the renin-angiotensin system (ACEI and 
ARB-2) should be prioritized owing to their neutral or favor-
able effects on metabolic alterations. We should remember 
that the majority of patients with hypertension and MetS 
will require combination therapy to achieve blood pressure 
goals. In these cases, the combination of choice is a renin-
angiotensin system blocker with a calcium channel blocker.
Dyslipidemia
The pharmacological treatment of dyslipidemia in patients 
with MetS must be carried out with the following 
considerations:
1. Always rule out secondary causes of dyslipidemia, either 
hypercholesterolemia or hypertriglyceridemia.
2. Treat in parallel to the existing risk factors. Atherogenic 
dyslipidemia may be particularly influenced by the degree 
of hydrocarbon metabolic control.
3. Address LDL-dependent and non-LDL-dependent dys-
lipidemia in both therapeutic objectives and follow-up.
4. Optimize measures aimed at appropriately modifying 
lifestyle, which will have to be intense and continuous 
even when pharmacological treatment in monotherapy 
or combination is necessary.
The primary objective is to achieve the LDL cholesterol 
target. To do so:
1. Adjust treatment according to basal concentration and 
the reduction necessary to reach the therapeutic target.
2. Select the lipid-lowering drug and dose required to 
achieve the LDL cholesterol target. Clinical guidelines 
recommend the initial use of statins and titrates up to the 
maximum tolerable dose, if necessary.
3. Use, if needed, combination treatment when monotherapy 
is insufficient, there is intolerance to the statin, or to 
reduce the chances of adverse effects by using an average 
statin dose in addition to another hypocholesterolemiant 
(ezetimibe, resin, or PCSK9 inhibitor).
However, despite conventional or optimal treatment 
focused on achieving LDL cholesterol targets, non-LDL-
dependent dyslipidemia frequently persists, referred by 
a rise in triglycerides, a drop in HDL cholesterol and an 
increase in small and dense LDL particles. This triad, known 
as atherogenic dyslipidemia, includes certain components 
that comprise the diagnostic criteria for MetS. In this 
context, the SEA recommends that once LDL cholesterol 
has been controlled, the persistence of an atherogenic 
dyslipidemia results in an evaluation of treatment with a 
fibrate, either in monotherapy or as an additional treatment 
to the statin.82
Possible interactions should be considered in cases of 
statin + fibrate combination treatment. Here, fenofibrate is 
the fibrate of choice to prevent the adverse effects of the statin 
+ gemfibrozil association.107
With respect to low HDL cholesterol, given the disap-
pointing efficacy results of clinical outcome studies with 
extended release of niacin or cholesteryl ester transfer 
protein inhibitors in addition to statin therapy, these drugs 
have failed as combination therapy with statins in lipid-
targeted approaches to reduce major cardiovascular events 
further in high-risk patients. For this reason, the majority 
of international clinical guidelines for the management of 
dyslipidemia or CVD prevention do not consider HDL cho-
lesterol a therapeutic goal.18,19,28,75 However, the beneficial 
effects of lifestyle changes, as well as statins and fibrates in 
raising HDL cholesterol concentrations should be taken into 
account.18,19,22,60,68
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Antiaggregation
For secondary prevention, the CV benefits of antiplatelet 
therapy with aspirin are well known. For this reason, all 
patients with MetS and CVD in any location should be treated 
with aspirin at low doses.
The best recommendation for the use of aspirin therapy 
in primary prevention is to follow current guidelines that 
attempt to balance the risks and benefits of this therapeutic 
strategy.108–110 In this respect, the potential bleeding risk should 
be borne in mind when considering aspirin therapy in primary 
prevention. In general, clinical guidelines recommend the use 
of aspirin in patients with a 10-year CV risk >10%, provided 
there are no contraindications. In clinical situations with a 
contraindication or resistance to aspirin, omega-3 fatty acids 
(2,800 mg) are a reasonable alternative to low-dose aspirin.111
Conclusion
In summary, MetS, a recognized risk factor for CVD and 
T2DM is unfortunately underrecognized, undertreated, and 
consequently undercontrolled. Its management is highly het-
erogeneous, which can hamper clinical decision-making and be 
a barrier to achieving the therapeutic goals for CVD and dia-
betes prevention. The treatment of MetS represents a growing, 
unmet therapeutic need in the CVD and diabetes prevention 
scenario. Although no single treatment for MetS as a whole 
currently exists, management should be targeted at treating 
the conditions contributing to it and possibly reversing the 
risk factors. In the present consensus document, professionals 
from different scientific societies involved in the management 
of different MetS components, reviewed the available scientific 
evidence focused basically on therapeutic aspects, and estab-
lished recommendations on therapeutic goals that facilitate 
homogenization in clinical decision-making. In this respect, 
the cornerstone therapeutic approach is lifestyle intervention, 
particularly weight reduction and physical activity, which can 
reverse the metabolic risk factors. However, pharmacological 
therapies may frequently be required to control more overt risk 
factors such as dyslipidemia and hypertension. Further clini-
cal trials on the safety and efficacy of novel therapies for this 
condition, as well as better designed clinical trials of existing 
therapies such as fibrates, are awaited.
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